A Phase 2 interventional study of enzalutamide and abiraterone acetate in Metastatic Castration-Resistant Prostate Cancer, sponsored by Astellas Pharma Global Development, Inc.. Completed at 1 site in United States. Open to male participants. Per ClinicalTrials.gov, last updated 2024-12-10.
Sponsored by Astellas Pharma Global Development, Inc. (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study was to explore the safety and tolerability of enzalutamide in combination with abiraterone acetate plus prednisone. Subjects diagnosed with cancer of the prostate that was getting worse and spreading to the bone despite receiving hormone treatment were enrolled and received study treatment until disease progression.
For the study duration, all subjects maintained androgen deprivation with a gonadotropin releasing hormone (GnRH) agonist or antagonist or orchiectomy. Study drug was administered until disease progression. Disease progression was defined as a composite endpoint consisting of either clinical deterioration, radiographic progression or prostate-specific antigen (PSA) progression according to the Prostate Cancer Clinical Trials Working Group 2 (PCWG2) criteria.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 60 is close to the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Astellas Pharma Global Development, Inc. is the lead sponsor of 207 studies on the registry; 23 are open to participants now.
Of its 82 completed or terminated interventional studies of FDA-regulated products, 38 (46%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Progressive disease defined as one or more of the following three criteria (Note: subjects who received an antiandrogen must demonstrate disease progression following discontinuation of antiandrogen):
Exclusion Criteria:
cardiovascular disease including:
History of significant bleeding disorder unrelated to cancer, including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received enzalutamide combined with abiraterone acetate once daily plus prednisone twice daily.
Drug: enzalutamide · Drug: abiraterone acetate · Drug: prednisone
Participants received 160 mg of enzalutamide orally once daily (4 capsules, 40 mg each).
Also known as: MDV3100
Participants received 1000 mg of abiraterone acetate orally once daily (4 tablets, 250 mg each).
Participants received 5 mg of prednisone orally twice daily (2 tablets, 5 mg each).
Number of Participants With Adverse Events (AEs)
A treatment-emergent adverse event (TEAE) was defined as an adverse event occurring or worsening between the start of study treatment date and the latest date of 30 days after the last dose date or the 30-day follow-up visit date, and not later than the data cut-off date or the date of death. AEs, including abnormal clinical laboratory values, were graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) guidelines (V4.03).
Time frame: From the first dose of study drug administration up 30 days following the last dose of study drug date, with a median duration of treatment of 10.1 months.
Change From Baseline in Testosterone Concentration in Bone Marrow Aspirate
Testosterone concentration in bone marrow aspirate was measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry.
Time frame: Baseline and Week 9
Change From Baseline in Dihydrotestosterone (DHT) Concentration in Bone Marrow Aspirate
DHT concentration in bone marrow aspirate was to be measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry. DHT bone data were not collected.
Time frame: Baseline and Week 9
Change From Baseline in Cortisol in Bone Marrow Aspirate
Cortisol in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
Time frame: Baseline and Week 9
Change From Baseline in Androstenedione in Bone Marrow Aspirate
Androstenedione in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
Time frame: Baseline and Week 9
Change From Baseline in Progesterone in Bone Marrow Aspirate
Progesterone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
Time frame: Baseline and Week 9
Change From Baseline in Pregnenolone in Bone Marrow Aspirate
Pregnenolone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
Time frame: Baseline and Week 9
Change From Baseline in Testosterone Concentration in Blood
Testosterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
Time frame: Baseline and Week 9
Change From Baseline in DHT Concentration in Blood
DHT concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry. The endpoint could not be analyzed since no participants had DHT levels over the lower limit of quantification (LLOQ).
Time frame: Baseline and Week 9
Change From Baseline in Cortisol Concentration in Blood
Cortisol concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
Time frame: Baseline and Week 9
Change From Baseline in Androstenedione Concentration in Blood
Androstenedione concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
Time frame: Baseline and Week 9
Change From Baseline in Progesterone Concentration in Blood
Progesterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
Time frame: Baseline and Week 9
Change From Baseline in Pregnenolone Concentration in Blood
Pregnenolone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
Time frame: Baseline and Week 9
Change From Baseline to End-of-Treatment (EoT) in Prostate-Specific Antigen (PSA) Levels
Prostate-specific antigen progression by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) was defined as a PSA increase ≥25% and ≥2 ng/ml above the post-baseline nadir, and which was confirmed by the first subsequent value of 3 or more weeks later.
Time frame: Baseline and EoT; the median duration of treatment was 10.1 months.
Progression Free Survival (PFS)
PFS was measured as the time from the date of first dose of any drug of the study combination treatment until the first evidence of documented progression (a composite endpoint consisting of radiographic progression or PSA progression by PCWG2 or clinical deterioration) or death in the absence of progression (whichever came first) or the date last known to be progression free. The Kaplan-Meier (KM) 95% CI was based on Brookmeyer and Crowley robust non-parametric method.
Time frame: Up to 1849 days
Percentage of Participants With Objective Response for Soft Tissue Lesions According to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST)
Objective response was based on RECIST version 1.1 for soft tissue lesion on Magnetic resonance imaging (MRI) / Computerized tomography (CT) and the PCWG2 guidelines for bone lesions on bone scans and was defined as partial response (PR) or complete response (CR) based on the investigators' assessments of target, non-target and new lesions while on study treatment. The 95% for objective response rate was based on exact binomial 95% confidence interval (Clopper-Pearson).
Time frame: Up to 1849 days
Bone Scan Response at EoT
PD: ≥1 of 3 criteria: PSA progression: ≥2 rising PSA levels, interval of ≥1 week between each determination. Soft tissue disease progression: RECIST 1.1. Bone disease progression: PCWG2 criteria (≥2 or new lesions on bone scan compared with prior scan). Target lesion CR: disappearance of all target lesions, PR as ≥30% decrease in sum of longest diameter (LD) of target lesions, referencing baseline sum LD, SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing smallest sum LD since treatment start, PD ≥20% increase in sum of LD of target lesions, referencing smallest sum LD recorded since treatment start or appearance of ≥1 new lesions. Non-target lesions CR: disappearance of all non-target lesions and normalization of tumor marker level, SD: persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits, PD: appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: EoT; the median duration of treatment was 10.1 months.
Change From Baseline to EoT in Bone Specific Alkaline Phosphatase
Bone metabolism marker bone specific alkaline phosphatase levels were derived from blood samples collected.
Time frame: Baseline and EoT; the median duration of treatment was 10.1 months.
Change From Baseline in Urine N-Telopeptide
Bone metabolism marker urine N-telopeptide levels were derived from urine samples collected.
Time frame: Baseline and Week 9
Androgen Receptor Signaling Assessed by Expression and Localization of Androgen Receptor (AR), CYP17 Expression, Splice Variants, and Pathways Linked With Non-classical AR Signaling and Bone Development
The endpoint was considered exploratory and no analysis was planned.
Time frame: Baseline and Week 9
All participants in this all male study were enrolled at 1 site in the United States (US).
| Milestone | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Started | 60 |
| Treated | 60 |
| Completed | 13 |
| Not completed | 47 |
| Withdrew: Progressive disease (pd) | 35 |
| Withdrew: Withdrawal by subject | 2 |
| Withdrew: Miscellaneous | 10 |
A treatment-emergent adverse event (TEAE) was defined as an adverse event occurring or worsening between the start of study treatment date and the latest date of 30 days after the last dose date or the 30-day follow-up visit date, and not later than the data cut-off date or the date of death. AEs, including abnormal clinical laboratory values, were graded using the National Cancer Institute-Common Terminology Criteria for Adverse Events (NCI-CTCAE) guidelines (V4.03).
| Participants | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Any TEAE | 60 |
| Enzalutamide-related TEAEs | 56 |
| Abiraterone-related TEAEs | 58 |
| Prednisone-related TEAEs | 16 |
| Deaths | 0 |
| Serious TEAEs | 10 |
| Enzalutamide-related serious TEAEs | 0 |
| Abiraterone-related serious TEAEs | 2 |
| Prednisone-related serious TEAEs | 0 |
| TEAEs leading to discontinuation of enzalutamide | 3 |
| Enza-related TEAEs leading to disc. of enza | 0 |
| Abiraterone-related TEAEs leading to disc. of enza | 0 |
| Prednisone-related TEAEs leading to disc. of enza | 0 |
| TEAEs leading to discontinuation of abiraterone | 1 |
| Abiraterone-related TEAEs leading to disc. of abi | 1 |
Testosterone concentration in bone marrow aspirate was measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry.
| pmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Testosterone Concentration in Bone Marrow Aspirate | -19.48 ± 257.923 |
DHT concentration in bone marrow aspirate was to be measured by laboratory results derived from bone marrow samples processed through liquid chromatography mass spectrometry. DHT bone data were not collected.
No measurements were reported for this outcome.
Cortisol in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
| nmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Cortisol in Bone Marrow Aspirate | -46.86 ± 48.022 |
Androstenedione in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
| nmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Androstenedione in Bone Marrow Aspirate | -0.32 ± 0.342 |
Progesterone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
| nmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Progesterone in Bone Marrow Aspirate | 1.16 ± 1.104 |
Pregnenolone in bone marrow aspirate was measured by laboratory results derived from bone marrow samples.
| pg/ml | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Pregnenolone in Bone Marrow Aspirate | 1381.44 ± 1513.324 |
Testosterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
| nmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Testosterone Concentration in Blood | -0.06 ± 0.068 |
DHT concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry. The endpoint could not be analyzed since no participants had DHT levels over the lower limit of quantification (LLOQ).
No measurements were reported for this outcome.
Cortisol concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
| nmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Cortisol Concentration in Blood | -48.81 ± 43.725 |
Androstenedione concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
| nmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Androstenedione Concentration in Blood | -0.24 ± 0.206 |
Progesterone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
| nmol/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Progesterone Concentration in Blood | 1.43 ± 2.434 |
Pregnenolone concentration in blood was measured by laboratory results derived from plasma samples. Plasma samples were derived from collected blood samples processed through liquid chromatography mass spectrometry.
| pg/ml | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Pregnenolone Concentration in Blood | 1507.42 ± 1699.335 |
Prostate-specific antigen progression by Prostate Cancer Clinical Trials Working Group 2 (PCWG2) was defined as a PSA increase ≥25% and ≥2 ng/ml above the post-baseline nadir, and which was confirmed by the first subsequent value of 3 or more weeks later.
| ug/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline to End-of-Treatment (EoT) in Prostate-Specific Antigen (PSA) Levels | 36.35 ± 444.355 |
PFS was measured as the time from the date of first dose of any drug of the study combination treatment until the first evidence of documented progression (a composite endpoint consisting of radiographic progression or PSA progression by PCWG2 or clinical deterioration) or death in the absence of progression (whichever came first) or the date last known to be progression free. The Kaplan-Meier (KM) 95% CI was based on Brookmeyer and Crowley robust non-parametric method.
| days | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Progression Free Survival (PFS) | 251 (147.0 to 337.0) |
Objective response was based on RECIST version 1.1 for soft tissue lesion on Magnetic resonance imaging (MRI) / Computerized tomography (CT) and the PCWG2 guidelines for bone lesions on bone scans and was defined as partial response (PR) or complete response (CR) based on the investigators' assessments of target, non-target and new lesions while on study treatment. The 95% for objective response rate was based on exact binomial 95% confidence interval (Clopper-Pearson).
| percentage of participants | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Percentage of Participants With Objective Response for Soft Tissue Lesions According to Response Evaluation Criteria in Solid Tumors 1.1 (RECIST) | 68.8 (41.3 to 89.0) |
PD: ≥1 of 3 criteria: PSA progression: ≥2 rising PSA levels, interval of ≥1 week between each determination. Soft tissue disease progression: RECIST 1.1. Bone disease progression: PCWG2 criteria (≥2 or new lesions on bone scan compared with prior scan). Target lesion CR: disappearance of all target lesions, PR as ≥30% decrease in sum of longest diameter (LD) of target lesions, referencing baseline sum LD, SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, referencing smallest sum LD since treatment start, PD ≥20% increase in sum of LD of target lesions, referencing smallest sum LD recorded since treatment start or appearance of ≥1 new lesions. Non-target lesions CR: disappearance of all non-target lesions and normalization of tumor marker level, SD: persistence of ≥1 non-target lesions and/or maintenance of tumor marker level above normal limits, PD: appearance of ≥1 new lesions and/or unequivocal progression of existing non-target lesions.
| Participants | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Complete Response (CR) | 1 |
| Progressive Disease (PD) | 15 |
| Non-CR/Non-PD | 35 |
| Not Evaluable | 1 |
Bone metabolism marker bone specific alkaline phosphatase levels were derived from blood samples collected.
| ug/L | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline to EoT in Bone Specific Alkaline Phosphatase | -5.18 ± 43.626 |
Bone metabolism marker urine N-telopeptide levels were derived from urine samples collected.
| nmolBCE/mmolcreat | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Change From Baseline in Urine N-Telopeptide | 29.35 ± 85.927 |
The endpoint was considered exploratory and no analysis was planned.
No measurements were reported for this outcome.
Collected over From the first dose of study drug administration up 30 days following the last dose of study drug date, with a median duration of treatment of 10.1 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Enzalutamide + Abiraterone + Prednisone | 0/60 (0%) | 9/60 (15%) | 60/60 (100%) |
| Event | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Angina pectorisCardiac disorders | 1/60 |
| Atrial fibrillationCardiac disorders | 1/60 |
| Macular oedemaEye disorders | 1/60 |
| Retinal vein occlusionEye disorders | 1/60 |
| UrosepsisInfections and infestations | 1/60 |
| Femur fractureInjury, poisoning and procedural complications | 1/60 |
| Hip fractureInjury, poisoning and procedural complications | 1/60 |
| Spinal compression fractureInjury, poisoning and procedural complications | 1/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/60 |
| Spinal cord compressionNervous system disorders | 1/60 |
| Event | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| FatigueGeneral disorders | 43/60 |
| HyperglycaemiaMetabolism and nutrition disorders | 41/60 |
| Blood alkaline phosphatase increasedInvestigations | 32/60 |
| Hot flushVascular disorders | 27/60 |
| Aspartate aminotransferase increasedInvestigations | 22/60 |
| AnaemiaBlood and lymphatic system disorders | 21/60 |
| Back painMusculoskeletal and connective tissue disorders | 20/60 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 19/60 |
| HypertensionVascular disorders | 19/60 |
| Alanine aminotransferase increasedInvestigations | 18/60 |
The analysis population for all baseline measures consisted of all participants who were enrolled in the study.
| Age, Continuous(Years) | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Mean | 65.4 ± 9.37 |
| Sex: Female, Male(Participants) | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Female | 0 |
| Male | 60 |
| Race/Ethnicity, Customized(Participants) | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| White | 51 |
| Black or African American | 6 |
| Asian | 2 |
| Other | 1 |
| Ethnicity(Participants) | Enzalutamide + Abiraterone + Prednisone |
|---|---|
| Not Hispanic or Latino | 57 |
| Hispanic or Latino | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as products terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Further details on Astellas' data sharing policy can be found at https://www.clinicaltrials.astellas.com/transparency/.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.
Access criteria: Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.
Data sharing details ↗ · www.clinicaltrials.astellas.com
Ran from Jul 2012 to primary completion in Jan 2018, 65 months.
Results were first posted in Feb 2019, 1 year 1 month after primary completion.
Of 179 industry-sponsored phase 2 interventional studies under Neoplasms, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 68. This study's 65 months is above that.
Counting every sponsor, half of 514 studies reached it within 52 months; a quarter within 33 and three quarters within 92.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Enzalutamide
Astellas Pharma Global Development, Inc. →